Along with the synergy that KRASG12C inhibitors exhibit with the aforementioned pathway inhibitors, the prospect of combining KRAS inhibitors with chemotherapy or immunotherapy introduces a more refined first-line treatment approach for NSCLC patients with the KRASG12C mutation. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.